Cara Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022
Cara Therapeutics, Inc. (Nasdaq: CARA) will host a conference call on November 7, 2022, at 4:30 p.m. ET to discuss third quarter 2022 financial results and provide a corporate update.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cara Therapeutics, Inc. (Nasdaq: CARA) will host a conference call on November 7, 2022, at 4:30 p.m. ET to discuss third quarter 2022 financial results and provide a corporate update. The company is known for its innovative KORSUVA® (difelikefalin) injection, the first FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in hemodialysis patients. Cara is also developing an oral version of difelikefalin and has initiated Phase 3 programs for pruritus in non-dialysis dependent advanced chronic kidney disease and atopic dermatitis.
Positive
- First FDA-approved treatment for moderate-to-severe pruritus in hemodialysis patients.
- Developing an oral formulation of difelikefalin.
- Initiated Phase 3 programs for pruritus in advanced chronic kidney disease and atopic dermatitis.
Negative
- None.
Details
News Market Reaction – CARA
The recorded move for CARA in the trading session of this news was +1.03%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
STAMFORD, Conn., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, November 7, 2022, at 4:30 p.m. ET to report third quarter 2022 financial results and provide a corporate update.
To participate in the conference call, please register here. Registrants will receive the dial-in numbers and a unique PIN.
A live audio webcast and archived replay of the call will be available under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.
About Cara Therapeutics
Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. The Company has completed a Phase 2 proof-of-concept trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. A Phase 2 proof-of-concept trial in primary biliary cholangitis patients with moderate-to-severe pruritus is ongoing. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.
MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com
INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
investor@caratherapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.